Biochemical and functional characterization of antigen presenting cell derived-exosomes: the design of a cell free cancer vaccine

Objective

This proposal is a combined R&D and demonstration project aimed at developing a novel therapeutic substance effective as cancer vaccine. The consortium has a unique expertise in a novel cell free vaccine i.e. the exosomes, 60-90 nm antigen presenting membrane vesicles of endosomal origin, secreted by antigen presenting cells. Characterization of exosome bioactivity will allow neosynthesis of biovectors endowed with targeting and tumor antigen transfer capacities to antigen presenting cells for active immunization. R&D objectives will be to:
1) define the biogenesis and biochemica composition of exasomes.
2) investigate their in vitra and in viva functians.
3) optimise the immunizing strategy using exosomes in preclinical tumor studies
4) design "universal" exosome based-cancer vaccine using good manufactoring procedures.

Demonstration phase involving the SME will show exosome safety and efficacy in immunizing metastatic cancer bearing patients.

Programme(s)

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Topic(s)

• 1.1.1.-3. - Key action The "Cell factory"

Funding Scheme

DEM - Demonstration contracts

Coordinator

INSTITUT GUSTAVE ROUSSY

Participants (5)

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

Address

Rapenburg 70
2311 EZ Leiden

ANOSYS S.A.

France

Address

Rue Pierre Fontaine, 1
91058 Evry

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

Address

Rue Lhomond 12
75005 Paris

UNIVERSITÀ DEGLI STUDI DI MILANO-BICOCCA

Italy

Address

Piazza Della Scienza 2
20126 Milano

VELINDRE HOSPITAL NHS TRUST

United Kingdom

Address

Velindre Road, Whitchurch
CF14 2TL Cardiff